Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: Adherence analysis A5084

AIDS Patient Care and STDs

Volumn 22, Issue 1, 2008, Pages 29-40

  Cohn, Susan E ^a,f   Umbleja, Triin ^b   Mrus, Joseph ^c   Bardeguez, Arlene D ^d   Andersen, Janet W ^b   Chesney, Margaret A ^e  

^a UNIVERSITY OF ROCHESTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Tibotec Therapeutics   (United States)

^d UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^e National Institutes of Health   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; DRUG ABUSE; FEMALE; HEALTH BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PREGNANCY; PRENATAL CARE; PROSPECTIVE STUDY; PUERPERIUM; SELF REPORT; SMOKING; VIRUS TRANSMISSION; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; POSTPARTUM PERIOD; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; QUESTIONNAIRES; RISK-TAKING; RNA, VIRAL; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; VITAMINS;

EID: 38149142836     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0053     Document Type: Article

References (40)

1. Public Health Service Task Force. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States October 12, 2006. www.aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf (Last accessed March 3, 2007).
2. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341:394-402.
3. Pbert L, Ockene JK, Zapka J, et al. A community health center smoking-cessation intervention for pregnant and postpartum women. Am J Prev Med 2004;26:377-385.
4. Anderson JE, Ebrahim S, Floyd L, Atrash H. Prevalence of risk factors for adverse pregnancy outcomes during pregnancy and the preconception period- United States, 2002-2004. Matern Child Health J 2006;10(Suppl 7):101-106.
5. Green-Raleigh K, Lawrence JM, Chen H, Devine O, Prue C. Pregnancy planning status and health behaviors among nonpregnant women in a California managed health care organization. Perspect Sex Reprod Health 2005;37:179-183.
6. Hitti J, Andersen J, McComsey GM, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: ACTG 5084. Am J Obstet Gynecol 2007;196:331.e1-7.
7. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000;12:255-266.
8. Cohn SE, Kammann E, Williams P, Currier JS, Chesney MA. Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:1129-1136.
9. Ebrahim SH, Decouffle P, Palakkathodi AS. Combined tobacco and alcohol use by pregnant and nonpregnant women in the United States. Obstet Gynecol 2000;96:767-771.
10. Ebrahim SH, Floyd RL, Merritt RK 2nd, Decoufle P, Holtzman D. Trends in pregnancy-related smoking rates in the United States, 1987-1996. JAMA 2000;283:361-366.
11. Fingerhut LA, Kleinman JC, Kendrick JS. Smoking before, during, and after pregnancy. Am J Public Health 1990;80:541-544.
12. Hans SL. Demographic and psychosocial characteristics of substance-abusing pregnant women. Clin Perinatol 1999;26:55-74.
13. Tuldra A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31(Suppl 3):S154-157.
14. Zorrilla CD, Santiago LE, Knubson D, et al. Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV. Cell Mol Biol (Noisy-legrand). 2003;49:1187-1192.
15. Centers for Disease Control and Prevention. Preconception Care Work Group. Recommendations to Improve Preconception Health and Health Care - United States. MMWR 2006;55:1-30. www.cdc.gov/mmwr/pdf/rr/rr5506.pdf (Last accessed February 11, 2007).
16. US Preventive Services Task Force. Counseling to prevent tobacco use and tobacco-caused disease: Recommendation statement. Rockville, MD: US Preventive Services Task Force, Agency for Healthcare Research and Quality, 2003.
17. Williamson D, Serdula MK, Kendrick JS, Binkin NJ. Comparing the prevalence of smoking in pregnant and nonpregnant women, 1985 to 1986. JAMA 1989;261:70-74.
18. Stanwood NL, Heiser JR, Pugliese M, Cohn SE. Contraception and fertility plans in a cohort of HIV-positive women in care. Contraception 2007;75:294-298.
19. Myer L, Morroni C, Rebe K. Prevalence and determinants of fertility intentions of HIV-infected women and men receiving antiretroviral therapy in South Africa. AIDS Patient Care STDs 2007;21:278-285.
20. Paiva V, Santos N, Franca-Junior I, Filipe E, Ayres JR, Segurado A. Desire to have children: Gender and reproductive rights of men and women living with HIV: A challenge to health care in Brazil. AIDS Patient Care STDs 2007;21:268-277.
21. Heard I, Sitta R, Lert F; the VESPA Study Group. Reproductive choice in men and women living with HIV: Evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA Study). AIDS 2007;21 (Suppl 1):S77-82.
22. Ogilvie GS, Palepu A, Remple VP, et al. Fertility intentions of women of reproductive age living with HIV in British Columbia, Canada. AIDS 2007;21(Suppl 1):S83-88.
23. Centers for Disease Control and Prevention. Incorporating HIV Prevention into the medical care of persons living with HIV. MMWR 2003;52:1-24. www.aidsinfo.nih.gov/ContentFiles/HIVPreventionIn-MedCare_TB.pdf (Last accessed February 10, 2007).
24. Olges JR, Murphy BS, Caldwell GG, Thornton AC. Testing practices and knowledge of HIV among prenatal care providers in a low seroprevalence state. AIDS Patient Care STDs 2007;21:187-194.
25. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-366.
26. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis 2001;33:1417-1423.
27. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005;191:339-347.
28. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-1183.
29. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002;16:1051-1058.
30. Thea DM, Steketee RW, Pliner V, et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS 1997;11:437-444.
31. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
32. Gulick RM. Adherence to antiretroviral therapy: How much is enough? Clin Infect Dis 2006;43:942-944.
33. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-941.
34. th Conference on Retroviruses and Opportunistic Infections. Denver, CO: February 2006.
35. Reynolds NR, Sun J, Nagaraja HN, Gifford A, Wu A, Chesney M. DACS 205D: Optimizing self-reported adherence with the ACTG questionnaires. Presented at the National ACTG Meeting. Baltimore, MD: December 5, 2006.
36. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990;150:1509-1510.
37. Podsadecki TJ, Vrijens BC, Tousset EP, Dode RA, Hanna GJ. White coat compliance patterns make therapeutic drug monitoring (TDM) a potentially unreliable tool for assessing long-term drug exposure. Poster #590 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO: February 2006.
38. Reynolds NR, Sun J, Nagaraja H, Chesney M, DACS205D Team. Optimizing measurement of self-reported adherence with the AIDS Clinical Trials Group (ACTG) Adherence Questionnaire: A cross protocol analysis. Presented at the XVI International AIDS Meeting. Toronto, Canada: August 2006.
39. Sackett DL, Haynes RB, Gibson ES, et al. Randomized clinical trial of strategies for improving medication compliance in primary hypertension. Lancet 1975;1:1205-1207.
40. The Henry J. Kaiser Family Foundation. Fact Sheet. Women and HIV/AIDS in the United States: Update December, 2006. www.kff.org/hivaids/6092.cfm. (Last accessed December 11, 2007).